Innovative research for malaria control driven by three collaborating parties: Swiss TPH, BASF and Promega
Madison, WI USA. (August 17, 2023)
The Swiss Tropical and Public Health Institute (Swiss TPH), in partnership with BASF and Promega, collaborate to research and develop novel insect control tools to help combat mosquito-borne diseases, such as malaria. The research project is funded by the Bill and Melinda Gates Foundation. To commemorate World Mosquito Day on August 20, it serves as a reminder of the ongoing need for investment in malaria prevention and control measures. Malaria remains a life-threatening infectious disease, affecting an estimated 247 million people globally in 2021.
The research, which is in its early stages, builds on previous studies in the field of Proteolysis Targeting Chimeras (PROTACs). PROTACs are a promising new class of therapeutic small molecules which modulate protein degradation within a cell. “The emerging cutting-edge technology – with a unique mode of action – may have great potential as a new approach in the control of insect disease vectors,” said Harold Bastiaans, Vice President Global Research Insecticides at BASF Agricultural Solutions. “It can potentially offer a powerful and cost-effective alternative, particularly important for tropical regions where insecticide-resistant mosquitoes are a growing concern.”
Dr. Elizabeth A. Caine, R&D Senior Scientist from Promega adds: “With the rise of PROTACs as promising anti-cancer therapeutics, we are excited to explore their potential application to degrade mosquito proteins as a method of insect control. Unlike conventional insecticides, PROTACs can be used to target and degrade proteins with precision.”
The collaboration started in September 2022 and is committed to a three to five year investigation. It combines complementary areas of expertise from each collaborator: BASF will leverage its expertise in chemistry design and synthesis to provide potential PROTACs to target mosquito specific proteins, while Promega will establish assays to test these molecules for their effectiveness to bind and degrade mosquito proteins in live cells. Swiss TPH brings expertise in mosquito biology, public health and epidemiology to the field and will be responsible for conducting in vivo testing of selected PROTACs.
The project underlines the commitment from all organizations involved to help find sustainable solutions for public health challenges and highlights the importance of continued innovation in the field. “Several diseases transmitted by mosquitoes are devastating and with insecticide resistance threatening the success of currently available tools, alternatives are much needed,” said Dr. Pie Müller, Head of Vector Biology at Swiss TPH. “We are proud of working together with BASF and Promega in our mission to develop new tools for mosquito control, and the support from the Bill and Melinda Gates Foundation shows just how important funding early research in new vector-control technologies is.” Preliminary results of the research collaboration are expected to be made public by 2025.
About BASF’s Agricultural Solutions division
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors.
About Swiss TPH
The Swiss Tropical and Public Health Institute (Swiss TPH) is a world-leading institute in global health with a particular focus on low- and middle-income countries. Associated with the University of Basel, Swiss TPH combines research, education and services at local, national and international levels. 900 people from 80 nations work at Swiss TPH focusing on infectious and non-communicable diseases, environment, society and health as well as health systems and interventions. www.swisstph.ch